Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ciprofloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby inhibiting DNA replication and transcription.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Urinary tract infections,Pyelonephritis,Chronic bacterial prostatitis,Lower respiratory tract infections,Acute sinusitis,Skin and skin structure infections,Bone and joint infections,Complicated intra-abdominal infections,Infectious diarrhea,Typhoid fever,Uncomplicated cervical and urethral gonorrhea,Inhalational anthrax (post-exposure),Plague,Febrile neutropenia (in combination)
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
400 mg IV every 8 hours for urinary tract infections; 400 mg IV every 12 hours for other infections. Infuse over 60 minutes.
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
3-5 hours in patients with normal renal function (creatinine clearance > 50 m L/min). In severe renal impairment (Cr Cl < 20 m L/min), half-life may extend to 6-8 hours. The terminal elimination half-life reflects the prolonged clearance of the drug from peripheral tissues such as skin and bone.
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Partially metabolized in the liver via CYP1A2 to four metabolites (desethylene-, sulfociprofloxacin, oxociprofloxacin, and formylciprofloxacin).
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Renal excretion accounts for approximately 50-70% of the dose as unchanged drug via glomerular filtration and tubular secretion. Additionally, about 15% is excreted as metabolites (oxo-ciprofloxacin, desethyleneciprofloxacin, sulfociprofloxacin). Biliary/fecal excretion accounts for 20-35%, primarily as unchanged drug and metabolites, with some enterohepatic recirculation.
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
20-40% bound to serum proteins, primarily albumin. Binding is concentration-independent and saturable at high doses ( > 400 mg), but clinically significant displacement interactions are rare due to low affinity.
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
2.5-3.0 L/kg. This large Vd indicates extensive tissue penetration with concentrations exceeding serum levels in kidney (2-3x), lung (2-3x), prostate (2x), and bone (1-2x). Penetration into cerebrospinal fluid is low (10-40% of serum levels) in non-inflamed meninges, but increases to 50-90% with inflammation.
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
Intravenous: 100% bioavailability (administered as a 0.9% sodium chloride solution). Oral ciprofloxacin bioavailability is 70-80% but is not relevant for this IV formulation.
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
Cr Cl 30-50 m L/min: 400 mg IV every 18-24 hours. Cr Cl 5-29 m L/min: 400 mg IV every 24 hours. Cr Cl <5 m L/min (on hemodialysis): 400 mg IV every 24 hours (administer after dialysis).
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
No specific adjustment for hepatic impairment; systemic exposure may be increased but no dose guidelines established.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
Neonates (0-7 days): 10 mg/kg IV every 12 hours. Infants (8-28 days): 10 mg/kg IV every 8 hours. Children (1 month - 5 years): 10 mg/kg IV every 8 hours (max 400 mg/dose). Children (5-17 years): 10 mg/kg IV every 8 hours (max 400 mg/dose) for complicated infections; 6-10 mg/kg IV every 8 hours for uncomplicated infections.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
Adjust based on renal function (Cr Cl); no age-specific dose modifications. Monitor for CNS effects and tendon disorders.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
Fluoroquinolones, including ciprofloxacin, are associated with an increased risk of tendinitis and tendon rupture in all ages. This risk is further increased in patients over 60 years of age, those taking corticosteroids, and patients with kidney, heart, or lung transplants.
None.
Tendon damage, including rupture, can occur within hours or up to several months after therapy,Exacerbation of myasthenia gravis symptoms,Peripheral neuropathy that may be irreversible,Central nervous system effects including seizures, dizziness, and increased intracranial pressure,Clostridium difficile-associated diarrhea,Phototoxicity,QT prolongation,Hypersensitivity reactions, including anaphylaxis,Hepatotoxicity,Blood glucose disturbances, including hypoglycemia and hyperglycemia
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Hypersensitivity to ciprofloxacin or any quinolone,Concomitant administration with tizanidine
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
No specific food interactions with IV ciprofloxacin; however, oral absorption is affected by dairy and calcium-fortified juices. For IV form, no dietary restrictions. Avoid excessive caffeine intake as ciprofloxacin may increase its effects.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
Ciprofloxacin is generally avoided during pregnancy, especially in the first trimester, due to potential arthropathy in animal studies. Human data do not demonstrate a significant increase in major malformations, but there is a theoretical risk of fetal cartilage damage. Use only if benefit outweighs risk and no safer alternative exists.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Ciprofloxacin is excreted into human breast milk. The milk-to-plasma ratio is approximately 0.85. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
No specific dose adjustment is recommended for pregnancy, but pharmacokinetic changes (increased volume of distribution, renal clearance) may necessitate careful monitoring of clinical response. Use lowest effective dose for shortest duration; intravenous formulation may be preferred in severe infections.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
Administer Cipro in Sodium Chloride 0.9% via IV infusion over 60 minutes to reduce risk of infusion site reactions. Monitor for tendonitis or tendon rupture, especially in patients over 60, those on corticosteroids, or with renal impairment. Avoid use in myasthenia gravis due to potential neuromuscular blockade. Dose adjustment required for Cr Cl < 30 m L/min; for Cr Cl 30-50 m L/min, usual dose every 12 hours. Ciprofloxacin can prolong QT interval; monitor ECG if concomitant with other QT-prolonging drugs or in patients with electrolyte abnormalities.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
This medication is given intravenously; you will receive it over at least 60 minutes.,Notify your healthcare provider immediately if you experience tendon pain, swelling, or rupture (especially in the Achilles tendon).,Report any signs of nerve damage such as pain, burning, tingling, numbness, or weakness.,Avoid excessive sun exposure or use sunscreen, as this drug may increase photosensitivity.,Inform your doctor if you have a history of seizures, QT prolongation, or myasthenia gravis.,Stay well hydrated unless otherwise instructed by your doctor.,Do not abruptly stop this medication without consulting your doctor.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Ciprofloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby inhibiting DNA replication and transcription.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 400 mg IV every 8 hours for urinary tract infections; 400 mg IV every 12 hours for other infections. Infuse over 60 minutes.. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Ciprofloxacin is generally avoided during pregnancy, especially in the first trimester, due to potential arthropathy in animal studies. Human data do not demonstrate a significant . ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.